SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-20-003618
Filing Date
2020-04-06
Accepted
2020-04-06 08:18:35
Documents
31
Period of Report
2020-04-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K f8-k.htm 8-K 38584
2 EX-99.1 ex-99d1.htm EX-99.1 44304
3 EX-99.2 ex-99d2.htm EX-99.2 65844
4 GRAPHIC ex-99d1g001.jpg GRAPHIC 2875
5 GRAPHIC ex-99d2g001.gif GRAPHIC 64318
6 GRAPHIC ex-99d2g002.gif GRAPHIC 52282
7 GRAPHIC ex-99d2g003.gif GRAPHIC 189579
8 GRAPHIC ex-99d2g004.gif GRAPHIC 79280
9 GRAPHIC ex-99d2g005.gif GRAPHIC 94600
10 GRAPHIC ex-99d2g006.gif GRAPHIC 87136
11 GRAPHIC ex-99d2g007.gif GRAPHIC 80936
12 GRAPHIC ex-99d2g008.gif GRAPHIC 97985
13 GRAPHIC ex-99d2g009.gif GRAPHIC 74075
14 GRAPHIC ex-99d2g010.gif GRAPHIC 58576
15 GRAPHIC ex-99d2g011.gif GRAPHIC 50726
16 GRAPHIC ex-99d2g012.gif GRAPHIC 55391
17 GRAPHIC ex-99d2g013.gif GRAPHIC 54586
18 GRAPHIC ex-99d2g014.gif GRAPHIC 51458
19 GRAPHIC ex-99d2g015.gif GRAPHIC 57870
20 GRAPHIC ex-99d2g016.gif GRAPHIC 47332
21 GRAPHIC ex-99d2g017.gif GRAPHIC 42867
22 GRAPHIC ex-99d2g018.gif GRAPHIC 35836
23 GRAPHIC ex-99d2g019.gif GRAPHIC 41223
24 GRAPHIC ex-99d2g020.gif GRAPHIC 36382
25 GRAPHIC ex-99d2g021.gif GRAPHIC 48072
26 GRAPHIC ex-99d2g022.gif GRAPHIC 79252
27 GRAPHIC ex-99d2g023.gif GRAPHIC 108316
28 GRAPHIC ex-99d2g024.gif GRAPHIC 66361
29 GRAPHIC ex-99d2g025.gif GRAPHIC 76246
30 GRAPHIC ex-99d2g026.gif GRAPHIC 62629
31 GRAPHIC ex-99d2g027.gif GRAPHIC 56389
  Complete submission text file 0001558370-20-003618.txt   2701795
Mailing Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038
Business Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

IRS No.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 20775811
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences